Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2007

01.08.2007 | Original Paper

Protective Effect of Soy Isoflavones and Activity Levels of Plasma Paraoxonase and Arylesterase in the Experimental Nonalcoholic Steatohepatitis Model

verfasst von: Bilal Ustundag, Ibrahim Halil Bahcecioglu, Kazım Sahin, Sevda Duzgun, Suleyman Koca, Funda Gulcu, Ibrahim Hanifi Ozercan

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Nonalcoholic steatohepatitis (NASH) is characterized by diffuse fatty infiltration in the liver and ballooning degeneration and inflammation in hepatocytes. We aimed to study the protective effect of soy isoflavones on experimental NASH and their effects on plasma paraoxanese and arylesterase levels in rats. Twenty-eight male rats were divided into four groups: Group 1 (n=7) received an isocaloric normal diet for 8 weeks, Group 2 (n=7) was fed an isocaloric basal diet plus oral soy isoflavone for 8 weeks (100 mg/kg in diet), Group 3 (n=7) received a special diet that was methionine and choline deficient (MCD) and rich in fat for 8 weeks, and Group 4 (n=7) was fed a special diet that was MCD and rich in fat plus oral soy isoflavone for 8 weeks (100 mg/kg in diet). Blood samples were collected to measure plasma malondialdehyde (MDA), paraoxanese, and arylesterase and biochemical parameters. Tissue samples were duly taken for histopathological examination and measurement of tissue MDA levels. Plasma MDA levels were higher in Group 3 than in Groups 1, 2, and 4 (P <0.01, P <0.05, and P <0.05 respectively). Liver tissue MDA levels were also significantly higher in Group 3 compared to Groups 1, 2, and 4 (P <0.001, P <0.001, and P <0.05 respectively). A significant decrease was found in the plasma and liver tissue MDA levels in Group 4 compared to Group 3 (P <0.05 and P <0.05, respectively). The activity levels of plasma paraoxanase and arylesterase were significantly higher in Group 2 than in Groups 1 and 3 (P <0.05 and P <0.01, respectively). Also, the plasma paraoxanase and arylesterase levels were significantly higher in Group 4 compared to Groups 1 and 3 (P <0.05 and P <0.01, respectively). A significant reduction was observed in Group 4 in steatosis, inflammation, necrosis, and fibrosis compared to Group 3 (P <0.05 for each). We conclude that soy isoflavones seem to be effective in preventing liver damage by decreasing lipid peroxidation in the NASH model induced by a MCD diet. They stimulate and increase the activity of the antioxidative paraoxanase enyzme while decreasing the total cholesterol and triglyceride levels.
Literatur
2.
Zurück zum Zitat Koteish A, Mae Diehl A (2002) Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16(5):679–690PubMedCrossRef Koteish A, Mae Diehl A (2002) Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16(5):679–690PubMedCrossRef
3.
Zurück zum Zitat Chitturi S, Farrell GC (2001) Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21(1):27–41PubMedCrossRef Chitturi S, Farrell GC (2001) Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21(1):27–41PubMedCrossRef
4.
Zurück zum Zitat Hensley K, Kotake Y, Sang H, Pye QN, Wallis GL, Kolker LM, Tabatabaie T, Stewart CA, Konishi Y, Nakae D, Floyd RA (2000) Dietary choline restriction causes complex I dysfunction and increased H2O2 generation in liver mitochondria. Carcinogenesis 21(5):983–989PubMedCrossRef Hensley K, Kotake Y, Sang H, Pye QN, Wallis GL, Kolker LM, Tabatabaie T, Stewart CA, Konishi Y, Nakae D, Floyd RA (2000) Dietary choline restriction causes complex I dysfunction and increased H2O2 generation in liver mitochondria. Carcinogenesis 21(5):983–989PubMedCrossRef
5.
6.
Zurück zum Zitat Hruszkewycz AM (1998) Evidence for mitochondrial DNA dmage by lipid peroxidation. Biochem Biophys Res Commun 153:191–197CrossRef Hruszkewycz AM (1998) Evidence for mitochondrial DNA dmage by lipid peroxidation. Biochem Biophys Res Commun 153:191–197CrossRef
7.
Zurück zum Zitat Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, Gentilini P, Dianzani MU (1993) Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 194:1044–1050PubMedCrossRef Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, Gentilini P, Dianzani MU (1993) Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 194:1044–1050PubMedCrossRef
8.
Zurück zum Zitat George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G (2003) Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 39:756–764PubMedCrossRef George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G (2003) Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 39:756–764PubMedCrossRef
9.
Zurück zum Zitat Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, de Hall PL (2003) Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 18:1272–1282PubMedCrossRef Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, de Hall PL (2003) Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 18:1272–1282PubMedCrossRef
10.
Zurück zum Zitat Martucci CP, Fishman J (1993) P450 enzymes of estrogen metabolism. Pharmacol Ther 57(2–3):237–257PubMedCrossRef Martucci CP, Fishman J (1993) P450 enzymes of estrogen metabolism. Pharmacol Ther 57(2–3):237–257PubMedCrossRef
11.
Zurück zum Zitat Kulling SE, Lehmann L, Metzler M (2002) Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. J Chromotogr 777:211–218CrossRef Kulling SE, Lehmann L, Metzler M (2002) Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. J Chromotogr 777:211–218CrossRef
12.
Zurück zum Zitat Anila L, Vijayalakshmi NR (2003) Antioxidant action of flavonoids from Mangifera indica and Emblica officinialis in hypercholesterolmic rats. Food Chem 83:569–574CrossRef Anila L, Vijayalakshmi NR (2003) Antioxidant action of flavonoids from Mangifera indica and Emblica officinialis in hypercholesterolmic rats. Food Chem 83:569–574CrossRef
13.
Zurück zum Zitat Choi C, Hyeyeon C, Park J, Song Y (2003) Supressive effects of genistein on oxidative stres and NF kB activation in RAW 264.7 macrophages. Biosci Biotechnol Biochem 67(9)1916–1922PubMedCrossRef Choi C, Hyeyeon C, Park J, Song Y (2003) Supressive effects of genistein on oxidative stres and NF kB activation in RAW 264.7 macrophages. Biosci Biotechnol Biochem 67(9)1916–1922PubMedCrossRef
14.
Zurück zum Zitat Rice Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB (1995) The relative antioxidant activities of plant derived polyphenolic flavonoids. Free Radical Res 22:375–383 Rice Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB (1995) The relative antioxidant activities of plant derived polyphenolic flavonoids. Free Radical Res 22:375–383
15.
Zurück zum Zitat Abad MJ, Bermejo P, Willar A (1995) The activity of flavonoids extracted from Tnacetum microphylumm DC (Compositae) on soybean lipoxygenase and prostaglandin synthetase. Gen Pharmacol 26:815–819PubMedCrossRef Abad MJ, Bermejo P, Willar A (1995) The activity of flavonoids extracted from Tnacetum microphylumm DC (Compositae) on soybean lipoxygenase and prostaglandin synthetase. Gen Pharmacol 26:815–819PubMedCrossRef
16.
Zurück zum Zitat Robak J, Gryglewsky RJ (1996) Bioactivity of flavonoids. Polish J Pharmacol Pharm 48:555–564 Robak J, Gryglewsky RJ (1996) Bioactivity of flavonoids. Polish J Pharmacol Pharm 48:555–564
17.
Zurück zum Zitat Wiseman H, O'Reilly JD, Adlercreutz H, Mallet AI, Bowey EA, Rowlland IR, Sanders TA (2000) Isoflavone phytoestrogens consumed in soy decrease F (2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 72(2):395–400PubMed Wiseman H, O'Reilly JD, Adlercreutz H, Mallet AI, Bowey EA, Rowlland IR, Sanders TA (2000) Isoflavone phytoestrogens consumed in soy decrease F (2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 72(2):395–400PubMed
18.
Zurück zum Zitat Djuric Z, Chen G, Doerge DR, Heilbrun LK, Kucuk O (2001) Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Lett 22(1):1–6CrossRef Djuric Z, Chen G, Doerge DR, Heilbrun LK, Kucuk O (2001) Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Lett 22(1):1–6CrossRef
19.
Zurück zum Zitat Demonty I, Lamrche B, Deshaies Y, Jacques H (2002) Role of soty isoflavones in the hypotrigliseridemic effect of soy protein in the rat. J Nutr Biochem 13:671–677PubMedCrossRef Demonty I, Lamrche B, Deshaies Y, Jacques H (2002) Role of soty isoflavones in the hypotrigliseridemic effect of soy protein in the rat. J Nutr Biochem 13:671–677PubMedCrossRef
20.
Zurück zum Zitat Beynen AC (1990) Mode of cholesteremic action of dieatary proteins. Monogr Atheroscler 16:153–159PubMed Beynen AC (1990) Mode of cholesteremic action of dieatary proteins. Monogr Atheroscler 16:153–159PubMed
21.
Zurück zum Zitat Sanchez A, Hubbard RW (1991) Plasma amino acids and the insulin glucagon ratio as a explanation for the dietary protein modulation of atherosclerosis. Med Hypothesis 36:27–32CrossRef Sanchez A, Hubbard RW (1991) Plasma amino acids and the insulin glucagon ratio as a explanation for the dietary protein modulation of atherosclerosis. Med Hypothesis 36:27–32CrossRef
22.
Zurück zum Zitat Forsyhte WA (1990) Dietary protein, cholesterol and thyroxine: a proposed mechanism. J Clin Nutr 68(Suppl):S101–S104 Forsyhte WA (1990) Dietary protein, cholesterol and thyroxine: a proposed mechanism. J Clin Nutr 68(Suppl):S101–S104
23.
Zurück zum Zitat Potter SM (1998) Soy protein and cardiovascular disease: the impact of bioactive components in soy. Nutr Rev 56:231–235PubMedCrossRef Potter SM (1998) Soy protein and cardiovascular disease: the impact of bioactive components in soy. Nutr Rev 56:231–235PubMedCrossRef
24.
Zurück zum Zitat Rinella ME, Green RM (2004) The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40(1):47–51PubMedCrossRef Rinella ME, Green RM (2004) The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40(1):47–51PubMedCrossRef
25.
Zurück zum Zitat Yagi K (1984) Assay for blood plasma and serum. Methods Enzmol 105:328–331 Yagi K (1984) Assay for blood plasma and serum. Methods Enzmol 105:328–331
26.
Zurück zum Zitat Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipide eproxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRef Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipide eproxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRef
27.
Zurück zum Zitat Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P (1995) Gln-Arg 192 polymorphysm of paraoxonase and coronary heart disease in y-type 2 diabetes. Lancet 346:869–872PubMedCrossRef Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P (1995) Gln-Arg 192 polymorphysm of paraoxonase and coronary heart disease in y-type 2 diabetes. Lancet 346:869–872PubMedCrossRef
28.
Zurück zum Zitat Juretic D, Tadjanovic M, Rekic B, Simeon Rudolf V, Reiner E, Barlicic M (2001) Serum paraoxonase actiivities in hemodialyzed uremic patients. Cohort study Croat Med J 42:146–150 Juretic D, Tadjanovic M, Rekic B, Simeon Rudolf V, Reiner E, Barlicic M (2001) Serum paraoxonase actiivities in hemodialyzed uremic patients. Cohort study Croat Med J 42:146–150
29.
Zurück zum Zitat Brunt E, Janney C, Bisceglie A, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis; a proposal for grading and staging the histopathologic lesions. Am J Gastroenterol 94:2467–2474PubMedCrossRef Brunt E, Janney C, Bisceglie A, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis; a proposal for grading and staging the histopathologic lesions. Am J Gastroenterol 94:2467–2474PubMedCrossRef
30.
Zurück zum Zitat Bahcecioglu IH, Yalniz M, Ataseven H, Bulbuller N, Kececi M, Demirdag K, Ozercan I, Ustundag B (2004) TNF-alpha and leptin in experimental liver fibrosis models induced by carbon tetrachloride and by common bile duct ligation. Cell Biochem Funct 22(6):359–363PubMedCrossRef Bahcecioglu IH, Yalniz M, Ataseven H, Bulbuller N, Kececi M, Demirdag K, Ozercan I, Ustundag B (2004) TNF-alpha and leptin in experimental liver fibrosis models induced by carbon tetrachloride and by common bile duct ligation. Cell Biochem Funct 22(6):359–363PubMedCrossRef
31.
Zurück zum Zitat Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, Hall PL (2003) Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 18(11):1272–1282PubMedCrossRef Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, Hall PL (2003) Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 18(11):1272–1282PubMedCrossRef
32.
Zurück zum Zitat Fort J, Oberti F, Pilette C, Veal N, Gallois Y, Douay O, Rousselet MC, Rosenbaum J, Cales P (1998) Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology 28(6):1525–1531PubMedCrossRef Fort J, Oberti F, Pilette C, Veal N, Gallois Y, Douay O, Rousselet MC, Rosenbaum J, Cales P (1998) Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology 28(6):1525–1531PubMedCrossRef
33.
Zurück zum Zitat Harrison SA, Kadakia S, Lang K, Schenker S (2002) Nonalcoholic steatohepatitis: What we know in the new millenium. Am J Gastroenterol 97:2714–2724PubMed Harrison SA, Kadakia S, Lang K, Schenker S (2002) Nonalcoholic steatohepatitis: What we know in the new millenium. Am J Gastroenterol 97:2714–2724PubMed
34.
35.
Zurück zum Zitat Day C, James O (1998) Steatohepatitis: A tale of two “hits”? Gastroenterology 114:842–845PubMedCrossRef Day C, James O (1998) Steatohepatitis: A tale of two “hits”? Gastroenterology 114:842–845PubMedCrossRef
36.
Zurück zum Zitat Lieber CS (1997) Role of oxidative stres and antioxidant therapy in alcoholic and nonalcholic liver disease. Adv Pharmacol 38:601–628PubMedCrossRef Lieber CS (1997) Role of oxidative stres and antioxidant therapy in alcoholic and nonalcholic liver disease. Adv Pharmacol 38:601–628PubMedCrossRef
37.
Zurück zum Zitat Aviram M (1996) Interaction of oxidized low density lipoproteins and increased atherogenicty of antioxidants. Eur J Clin Chem Clin Biochem 34:599PubMed Aviram M (1996) Interaction of oxidized low density lipoproteins and increased atherogenicty of antioxidants. Eur J Clin Chem Clin Biochem 34:599PubMed
38.
Zurück zum Zitat Zhishen J, Mengencheng T, Jianmibg W (1999) The determination of flavonoid contents in mulberry and their scavenging effects on superoxide radicals. Food Chem 64:555–559CrossRef Zhishen J, Mengencheng T, Jianmibg W (1999) The determination of flavonoid contents in mulberry and their scavenging effects on superoxide radicals. Food Chem 64:555–559CrossRef
39.
Zurück zum Zitat Gryglewski RJ, Korbut R, Robak J, Swies J (1987) On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 36(3):317–322PubMedCrossRef Gryglewski RJ, Korbut R, Robak J, Swies J (1987) On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 36(3):317–322PubMedCrossRef
40.
Zurück zum Zitat Lee MK, Bok SH, Jeong TS, Moon SS, Lee SE, Park YB, Choi MS (2002) Supplementation of Naringenin and its synthetic derivative alters antioxidant enzyme activities of erythrocyte and liver in high cholesterol fed rats. Biorg Med Chem 10:2239–2244CrossRef Lee MK, Bok SH, Jeong TS, Moon SS, Lee SE, Park YB, Choi MS (2002) Supplementation of Naringenin and its synthetic derivative alters antioxidant enzyme activities of erythrocyte and liver in high cholesterol fed rats. Biorg Med Chem 10:2239–2244CrossRef
41.
Zurück zum Zitat Seo HJ, Jeong KS, Lee MK, Park YB, Jung UJ, Kim HJ, Choi MS (2003) Role of naringenin suplement in regulation of lipid and ethanol metabolism in rats. Life Sci 73:933–946PubMedCrossRef Seo HJ, Jeong KS, Lee MK, Park YB, Jung UJ, Kim HJ, Choi MS (2003) Role of naringenin suplement in regulation of lipid and ethanol metabolism in rats. Life Sci 73:933–946PubMedCrossRef
42.
Zurück zum Zitat Fuhrman B, Aviram M (2001) Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr Opin Lipidol 12(1):41–48PubMedCrossRef Fuhrman B, Aviram M (2001) Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr Opin Lipidol 12(1):41–48PubMedCrossRef
43.
Zurück zum Zitat Beltowski J, Wojcicka G, Jamroz A (2003) Leptin decreases plasma paroxonase 1 activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atheroclerosis 170:21–29CrossRef Beltowski J, Wojcicka G, Jamroz A (2003) Leptin decreases plasma paroxonase 1 activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atheroclerosis 170:21–29CrossRef
44.
Zurück zum Zitat Beltowski J, Wojcica G, Mydlardrczyk M, Jamroz A (2002) The effect of peroxisome prolifarator activated receptors alpha (PPAR a) agonist fenofibrate on lipid peroxidation, total antioxidant capacity and plasma paraoxonase 1 (PON1) activity. J Physiol Pharmacol 53:463–475PubMed Beltowski J, Wojcica G, Mydlardrczyk M, Jamroz A (2002) The effect of peroxisome prolifarator activated receptors alpha (PPAR a) agonist fenofibrate on lipid peroxidation, total antioxidant capacity and plasma paraoxonase 1 (PON1) activity. J Physiol Pharmacol 53:463–475PubMed
45.
Zurück zum Zitat Starkel P, Sempoux C, Leclercq I, Herin M, Deby C, Desager JP, Horsmans Y (2003) Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 39(4):538–546PubMedCrossRef Starkel P, Sempoux C, Leclercq I, Herin M, Deby C, Desager JP, Horsmans Y (2003) Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 39(4):538–546PubMedCrossRef
Metadaten
Titel
Protective Effect of Soy Isoflavones and Activity Levels of Plasma Paraoxonase and Arylesterase in the Experimental Nonalcoholic Steatohepatitis Model
verfasst von
Bilal Ustundag
Ibrahim Halil Bahcecioglu
Kazım Sahin
Sevda Duzgun
Suleyman Koca
Funda Gulcu
Ibrahim Hanifi Ozercan
Publikationsdatum
01.08.2007
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9251-9

Weitere Artikel der Ausgabe 8/2007

Digestive Diseases and Sciences 8/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.